Benevolent Platform News Today

The target was discovered leveraging the AI-driven drug discovery platform of BenevolentAI and validated by AstraZeneca.

Regulatory News: BenevolentAI , a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of...

BenevolentAI announces positive topline safety and pharmacokinetic data from the Phase Ia clinical study of BEN-8744 in healthy volunteers London, UK, 25 March...

AI provider BenevolentAI has announced the appointment of Dr. Click to read more...

Regulatory News: Posted to shareholders on 27 December 2023 Dear Shareholders AI is becoming an accepted and validated approach to drug discovery and development with long term structural...

Shareholder letter December 2023 Dear Shareholders AI is becoming an accepted and validated approach to drug discovery and development with...

WASHINGTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Global Artificial Intelligence in the Drug Discovery Market has been steadily growing over the years due to the growing demand for personalized medicine, the requirement for effective drug development procedures, and partnerships between pharmaceutical companies and AI technology providers. By analyzing enormous volumes of biological and chemical data, AI algorithms and data analytic approaches are revolutionizing

Research, presented by AstraZeneca, provides information on the biological validation of Serum Response Factor as a potential target for idiopathic pulmonary fibrosis The target was discovered

Marketplace and partnership promote information sharing and collaboration across the biopharma industry to accelerate new drug discovery and development. ... | May 16, 2023

BenevolentAI Result of Annual General Meeting London, UK, 4 May 2023: BenevolentAI , a leading, clinical-stageAI-enabled drug discovery and... | May 4, 2023